Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J.
Madorsky Rowdo FP, et al. Among authors: davis mb.
Cancer Lett. 2024 Mar 1;584:216608. doi: 10.1016/j.canlet.2024.216608. Epub 2024 Jan 9.
Cancer Lett. 2024.
PMID: 38199587
Free article.